Clinical Trial: Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis
Brief Summary: To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, are able to produce reliable changes in the bone marker in a severe osteoporotic population
Detailed Summary:
Sponsor: Eli Lilly and Company
Current Primary Outcome: To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, is able to produce reliable changes in the bone marker in a severe osteoporotic population in Puerto Rico.
Original Primary Outcome: Same as current
Current Secondary Outcome:
- To test the hypothesis that this group of patients will have a high score in the survey used by IOF as an instrument to check risk factors.
- Test the hypothesis that patients will have a high score in the survey used by IOF as an instrument to check risk factors.
Original Secondary Outcome: Same as current
Information By: Eli Lilly and Company
Dates:
Date Received: September 18, 2007
Date Started: April 2003
Date Completion:
Last Updated: September 18, 2007
Last Verified: September 2007
